Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation
1995; 92: 785–789.
Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet
2013; 381: 242–255.
Zhao P, Wang JG, Gao P, Li X, Brewer R. Sudden unexpected death from natural diseases: fifteen years’ experience with 484 cases in Seychelles. J Forensic Leg Med
2016; 37: 33–38.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA
2002; 287: 1308–1320.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol
2011; 58: e212–e260.
Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol
2015; 65: 1249–1254.
Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol
2012; 60: 705–715.
Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. Int J Cardiol
2011; 152: 258–259.
Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest
1994; 93: 280–285.
Hwang TH, Lee WH, Kimura A, et al. Early expression of a malignant phenotype of familial hypertrophic cardiomyopathy associated with a Gly716Arg myosin heavy chain mutation in a Korean family. Am J Cardiol
1998; 82: 1509–1513.
Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol
2002; 39: 2042–2048.
Frisso G, Limongelli G, Pacileo G, et al. A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy. Clin Genet
2009; 76: 91–101.
Rai TS, Ahmad S, Bahl A, et al. Genotype phenotype correlations of cardiac beta-myosin heavy chain mutations in Indian patients with hypertrophic and dilated cardiomyopathy. Mol Cell Biochem
2009; 321: 189–196.
Choi JO, Yu CW, Chun NJ, et al. Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations. Clin Cardiol
2010; 33: 430–438.
Pytel P, Husain A, Moskowitz I, et al. Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy. Cardiovasc Pathol
2010; 19: e33–e36.
Garcia-Giustiniani D, Arad M, Ortiz-Genga M, et al. Phenotype and prognostic correlations of the converter region mutations affecting the beta myosin heavy chain. Heart
2015; 101: 1047–1053.
Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell
1990; 62: 999–1006.
McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest
2013; 123: 19–26.
Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
2004; 44: 602–610.
Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation
2003; 107: 2227–2232.
Abchee A, Marian AJ. Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. J Investig Med
1997; 45: 191–196.
Huang X, Song L, Ma AQ, et al. A malignant phenotype of hypertrophic cardiomyopathy caused by Arg719Gln cardiac beta-myosin heavy-chain mutation in a Chinese family. Clin Chim Acta
2001; 310: 131–139.
McKenna WJ. Hypertrophic cardiomyopathy: an update. Cardiologia
1993; 38: 277–281.
Miller G, Colegrave M, Peckham M. N232S, G741R and D778G beta-cardiac myosin mutants, implicated in familial hypertrophic cardiomyopathy, do not disrupt myofibrillar organisation in cultured myotubes. FEBS Lett
2000; 486: 325–327.